Open AccessThe Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed‐Dose Combination in Hypertensive Patients With and Without High Cardiovascular Risk
Author(s) -
Weir Matthew R.,
Neutel Joel M.,
Bhaumik Amitabha,
Obaldia Maria Elena De,
Lapuerta Pablo
Publication year - 2007
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2007.07805.x
Subject(s) - irbesartan , medicine , hydrochlorothiazide , tolerability , blood pressure , type 2 diabetes , diabetes mellitus , post hoc analysis , cardiology , adverse effect , endocrinology
A post hoc pooled analysis of 2 multicenter, randomized, double‐blind, active‐controlled force‐titration studies assessed the antihypertensive efficacy and tolerability of 7 to 8 weeks' once‐daily fixed‐dose irbesartan/hydrochlorothiazide (HCTZ) 300/25 mg in 796 stage 1 or 2 hypertensive patients according to age (65 years or older or younger than 65) (n=121 or 675) and presence or absence of obesity (n=378 or 414), type 2 diabetes (n=99 or 697), and high World Health Organization‐defined cardiovascular risk (n=593 or 202). Systolic/diastolic blood pressure reductions (27–31/16–22 mm Hg) were similar regardless of age, obesity, and type 2 diabetes status and were greater in high‐ vs low‐risk patients. Dizziness (2.0%–3.7%), hypotension (0%–0.7%), and syncope (0%) were rare and not centered in any subgroup. There was no hypotension in the elderly or in type 2 diabetics. Irbesartan/HCTZ provided consistent blood pressure lowering and tolerability regardless of age, obesity, and type 2 diabetes and greater efficacy in patients with high cardiovascular risk.